- Home
- CXE vs FATE Comparison
CXE vs FATE Comparison
Compare CXE & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CXE | FATE |
|---|---|---|
| Founded | 1989 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.6M | 125.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | CXE | FATE |
|---|---|---|
| Price | $3.72 | $1.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 68.5K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $53.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.40 | $0.91 |
| 52 Week High | $3.88 | $1.94 |
Technical Indicators
Market Signals| Indicator | CXE | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 53.14 |
| Support Level | $3.68 | $0.95 |
| Resistance Level | $3.76 | $1.45 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 51.85 |
Price Performance
Historical ComparisonAbout CXE MFS High Income Municipal Trust
Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company's investment portfolio has shares from the industry Healthcare, Airports, and Secondary Schools.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.